You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

CLINICAL TRIALS PROFILE FOR ETOMIDATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Etomidate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00175747 ↗ A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) Completed National Cancer Institute (NCI) Phase 2/Phase 3 2000-01-01 Studies in animals suggest that inhaled budesonide may prevent the occurrence of lung cancer. We conducted a clinical trial to determine the effects of inhaled budesonide in smokers who had precancerous lesions in the breathing tubes (i.e. bronchial dysplasia.
NCT00175747 ↗ A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) Completed University of British Columbia Phase 2/Phase 3 2000-01-01 Studies in animals suggest that inhaled budesonide may prevent the occurrence of lung cancer. We conducted a clinical trial to determine the effects of inhaled budesonide in smokers who had precancerous lesions in the breathing tubes (i.e. bronchial dysplasia.
NCT00248729 ↗ Effectiveness and Safety Study of Etomidate Versus Midazolam to Help Place a Breathing Tube Outside of the Hospital. Completed St. Luke's Hospital, Pennsylvania Phase 2 2002-10-01 The objective of this study was to compare the utility of etomidate and midazolam in helping patients to relax when there was a need for the placement of a ventilation tube by medics who were transporting patients to a hospital in an ambulance.
NCT00415701 ↗ Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery Completed University Hospital Inselspital, Berne Phase 4 2006-11-01 The purpose of this study is to evaluate the effect of a single dose of etomidate for patients undergoing cardiac surgery with the use of cardiopulmonary bypass (CPB) on post-CPB adrenocortical responsiveness, on requirements of hemodynamic support, and on use of intensive care resources.
NCT00440102 ↗ Ketamine Versus Etomidate During Rapid Sequence Intubation: Consequences on Hospital Morbidity Completed Assistance Publique - Hôpitaux de Paris Phase 4 2007-04-01 The expected benefit is a reduction of the morbidity of patients admitted in the intensive care unit having received ketamine for intubation.
NCT00441792 ↗ The Effect of Etomidate on Patient Outcomes After Single Bolus Doses Completed Emergency Medicine Foundation N/A 2007-10-01 The primary aim is to determine the difference in hospital length of stay between septic patients given etomidate and those given midazolam for induction during rapid sequence intubation (RSI) in the emergency department. To achieve this aim we plan to perform a prospective randomized trial measuring the length of stay of patients meeting sepsis criteria and requiring intubation. The investigators will compare in-hospital mortality rates between patients given etomidate and patients given midazolam for induction. In addition to hospital length of stay, secondary endpoints between the two groups will include length of stay in the intensive care unit, death within 48 hours of admission, and total number of days intubated. Research Hypothesis: In adult patients presenting to the emergency department with sepsis and requiring rapid sequence intubation, the length of stay of patients given etomidate will be greater than that of patients given the alternative agent midazolam for induction.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Etomidate

Condition Name

Condition Name for Etomidate
Intervention Trials
Anesthesia 9
Coronary Artery Disease 5
Depression 4
General Anesthesia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Etomidate
Intervention Trials
Depression 7
Depressive Disorder 6
Coronary Artery Disease 5
Depressive Disorder, Major 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Etomidate

Trials by Country

Trials by Country for Etomidate
Location Trials
United States 27
China 17
France 6
Poland 4
Canada 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Etomidate
Location Trials
Minnesota 3
Pennsylvania 3
California 2
Tennessee 2
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Etomidate

Clinical Trial Phase

Clinical Trial Phase for Etomidate
Clinical Trial Phase Trials
Phase 4 46
Phase 3 9
Phase 2/Phase 3 4
[disabled in preview] 40
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Etomidate
Clinical Trial Phase Trials
Completed 45
Unknown status 20
Recruiting 18
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Etomidate

Sponsor Name

Sponsor Name for Etomidate
Sponsor Trials
Henan Provincial People's Hospital 3
Tianjin Medical University General Hospital 3
The Cleveland Clinic 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Etomidate
Sponsor Trials
Other 115
Industry 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Etomidate: Clinical Trials, Market Analysis, and Projections

Introduction to Etomidate

Etomidate is a short-acting intravenous anesthetic agent widely used for the induction of general anesthesia and for sedation in critical care settings. It is known for its minimal impact on cardiovascular stability, making it a preferred choice in patients with compromised cardiac function.

Clinical Trials Update

Etomidate vs Propofol for In-Hospital Complications

A significant clinical trial, the Etomidate vs Propofol for In-hospital Complications (EPIC) study, was conducted to compare the safety and efficacy of etomidate and propofol in older patients undergoing elective abdominal surgery. Here are the key findings:

  • Patient Demographics and Randomization: The study involved 1944 patients aged 65-80 years, randomized 1:1 to receive either etomidate or propofol. The trial was conducted at 22 tertiary hospitals in China between August 2017 and November 2020[1].
  • Primary End Points: The primary end point of in-hospital major complications occurred in 9.3% of the etomidate group and 8.7% of the propofol group, meeting the noninferiority criterion. There were no significant differences in individual complication types except for pulmonary complications, which were more common in the etomidate group (2.0% vs 0.5%)[1].
  • Mortality Rates: No difference in mortality was observed between the groups at 6 and 12 months post-surgery[1].
  • Cortisol Levels: Etomidate was associated with lower cortisol levels at the end of surgery compared to propofol[1].

Safety and Adverse Events

A Phase 1 study on ET-26, a formulation related to etomidate, highlighted the safety profile of etomidate-like compounds. The study found that the most common adverse events were myoclonus (53.8%) and injection pain (47.4%), which were transient and resolved spontaneously. No severe adverse events occurred, and vital signs remained stable[4].

Market Analysis

Market Size and Growth

The global etomidate market is experiencing steady growth driven by several factors:

  • Current Market Size: The market was valued at $2.3 billion in 2023 and is projected to reach $3.2 billion by 2033, growing at a CAGR of 3.6% from 2024 to 2033[2].
  • Forecasted Growth: Another report estimates the market size to be over $80.42 billion in 2023, projected to reach $121.12 billion by 2036, with a CAGR of 3.2% during the forecast period[3].

Market Segmentation

The etomidate market is segmented based on product type, end user, and region:

  • Product Type: The market is divided into induction agents and fat emulsions. Fat emulsions are expected to acquire the largest share due to their lesser side effects and role in energy metabolism during operations[3].
  • End User: The market is classified into hospitals, ambulatory surgical centers, and others. Ambulatory surgical centers are anticipated to hold the largest share due to the high usage of etomidate in trauma and cardiovascular emergencies[3].
  • Regional Outlook: Asia-Pacific is expected to be the largest regional market, driven by favorable government policies and rapidly growing healthcare infrastructure. North America is also a significant market, driven by advanced healthcare infrastructure and a high incidence of chronic conditions[2][3].

Key Market Drivers

  • Increasing Demand in Emergency and Surgical Procedures: The growing prevalence of surgeries and critical care procedures drives the demand for safe and effective anesthetics like etomidate[2].
  • Favorable Hemodynamic Profile: Etomidate's minimal impact on cardiovascular stability makes it a preferred choice in various medical settings[2].
  • Research and Development: Ongoing R&D into new formulations and delivery methods, as well as its use in animal testing, further propels the market growth[3].

Regional Market Outlook

  • Asia-Pacific: This region is set to account for the largest revenue share due to favorable government policies and growing healthcare infrastructure[3].
  • North America: The region is expected to develop significantly, driven by advanced healthcare infrastructure, high healthcare spending, and a high incidence of chronic conditions[2].

Market Projections

Future Growth Opportunities

  • Increasing Healthcare Expenditure: The rise in healthcare spending globally, particularly in emerging markets, presents significant growth opportunities for etomidate market players[2].
  • Growing Geriatric Population: The increasing need for medical interventions among the elderly population is expected to drive the demand for etomidate[2].
  • Advancements in Formulations: Research into new formulations and delivery methods, such as fat emulsions, is expected to boost market growth[3].

Challenges and Opportunities

  • Adverse Events: Common adverse events like myoclonus and injection pain, although transient, need to be managed effectively to enhance patient comfort[4].
  • Regulatory Environment: Favorable government policies and regulations regarding the use of etomidate in medical procedures are crucial for market growth[3].

Key Takeaways

  • Clinical Safety: Etomidate is generally safe, with minimal cardiovascular effects, but it may cause transient adverse events like myoclonus and injection pain.
  • Market Growth: The global etomidate market is projected to grow at a CAGR of 3.6% from 2024 to 2033, driven by increasing demand in emergency and surgical procedures.
  • Regional Dominance: Asia-Pacific and North America are expected to be the leading regions in the etomidate market.
  • Market Segmentation: Fat emulsions and ambulatory surgical centers are anticipated to be significant segments in the market.

FAQs

What are the primary uses of etomidate?

Etomidate is primarily used for the induction of general anesthesia and for sedation in critical care settings, particularly in emergency and surgical procedures.

What are the common adverse events associated with etomidate?

Common adverse events include myoclonus and injection pain, which are typically transient and resolve spontaneously.

Which region is expected to dominate the etomidate market?

Asia-Pacific is expected to account for the largest revenue share in the etomidate market, driven by favorable government policies and growing healthcare infrastructure.

What is the projected growth rate of the global etomidate market?

The global etomidate market is projected to grow at a CAGR of 3.6% from 2024 to 2033.

What are the key drivers of the etomidate market?

Key drivers include the increasing demand in emergency and surgical procedures, favorable hemodynamic profile, and ongoing research and development activities.

Sources

  1. JAMA Surgery: "Effect of Etomidate vs Propofol for Total Intravenous Anesthesia on In-Hospital Complications in Older Patients Undergoing Elective Abdominal Surgery: A Randomized Clinical Trial"[1].
  2. Allied Market Research: "Etomidate Market Size, Share and Growth Report, 2033"[2].
  3. Research Nester: "Etomidate Market Size, Forecast Report 2037"[3].
  4. PubMed: "Phase 1 single-centre placebo- and etomidate-controlled study in healthy volunteers"[4].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.